Drug interaction study for flonoltinib tablets in healthy adults
This trial tests how flonoltinib tablets interact with other medicines or foods in healthy adults. Taking part helps doctors understand safe dosing and potential side effects before the drug is given to patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a healthy adult aged 18 to 45 years
- Weigh at least 50 kg if male, or 45 kg if female, with a body mass index (BMI) between 19.0 and 26.0
- Be able to fully understand and sign a consent form
- Have no history of hepatitis B, hepatitis C, HIV, syphilis, or other infections listed
- Have no history of drug abuse or use of illegal drugs
- Avoid alcohol, grapefruit juice, coffee, tea, cola, chocolate, and energy drinks for 48 hours before entering the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how the drug clifutinib is processed by the body when taken with other medicines (itraconazole, fluconazole, or efavirenz). Healthy volunteers will receive a single dose of clifutinib plus one of these other drugs to see how they affect each other.
This study tests a new pill, flonoltinib, for people with polycythemia vera whose blood counts are hard to control and who have not responded well to or couldn't tolerate current treatments. The goal is to see if the pill can lower the number of red blood cells and reduce symptoms, potentially reducing the need for frequent blood removal procedures.
This study tests how well the body absorbs a drug called zongertinib when it is given as tablets from two different manufacturers, with or without food. It helps researchers understand the best way to take the medicine.
This trial tests a new tablet, Flonoltinib, for people with medium-to-high risk myelofibrosis whose prior JAK inhibitor treatment stopped working, caused side effects, or wasn't tolerated. The goal is to see if this new drug can help reduce spleen size and improve symptoms.
This study is for healthy men to see how a new drug called vimseltinib affects a protein in your body that helps remove other drugs. Participation will help your doctors understand how to use this drug safely in the future.
This trial is testing a new pill for people with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It aims to see if the drug can help manage the disease and offer a new treatment option for those who may have limited choices.
Hear when a new Drug Interaction Research trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.